E
Ed Whalen
Researcher at Pfizer
Publications - 55
Citations - 2404
Ed Whalen is an academic researcher from Pfizer. The author has contributed to research in topics: Pregabalin & Placebo. The author has an hindex of 16, co-authored 52 publications receiving 2251 citations. Previous affiliations of Ed Whalen include University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
TL;DR: The data suggest that donepezil’s benefits extend into more advanced stages of AD than those previously investigated, with very good tolerability.
Journal ArticleDOI
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens
TL;DR: Pregabalin dosing aimed at optimal balance of efficacy and tolerability provides significant pain relief and may reduce risks for AEs and therapy discontinuation.
Journal ArticleDOI
Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.
David M. Simpson,Giovanni Schifitto,David B. Clifford,T.K. Murphy,E. Durso-De Cruz,Paul Glue,Ed Whalen,Birol Emir,G. N. Scott,Roy Freeman +9 more
TL;DR: Pregabalin was well-tolerated, but not superior to placebo in the treatment of painful HIV neuropathy, and factors predicting analgesic response in HIV neuropathic pain syndromes warrant additional research.
Journal ArticleDOI
A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury
Diana D. Cardenas,Edward C Nieshoff,Kota Suda,Shin Ichi Goto,Luis Sanin,Takehiko Kaneko,Jonathan Sporn,Bruce Parsons,Matt Soulsby,Ruoyong Yang,Ed Whalen,Joseph M. Scavone,Makoto M. Suzuki,Lloyd Knapp +13 more
TL;DR: Pregabalin treatment resulted in statistically significant improvements over placebo for all primary and key secondary outcome measures and demonstrates that pregabalin is effective and well tolerated in patients with neuropathic pain due to SCI.
Journal ArticleDOI
Pregabalin for Postherpetic Neuralgia: Placebo-Controlled Trial of Fixed and Flexible Dosing Regimens on Allodynia and Time to Onset of Pain Relief
TL;DR: In this article, the authors examined the time to onset of pain relief and improvement in allodynia in 269 patients with postherpetic neuralgia in a 4-week randomized trial.